Biomarkers for prostate cancer: present challenges and future opportunities

Prostate cancer (PCa) has variable biological potential with multiple treatment options. A more personalized approach, therefore, is needed to better define men at higher risk of developing PCa, discriminate indolent from aggressive disease and improve risk stratification after treatment by predicting the likelihood of progression. This may improve clinical decision-making regarding management, improve selection for active surveillance protocols and minimize morbidity from treatment. Discovery of new biomarkers associated with prostate carcinogenesis present an opportunity to provide patients with novel genetic signatures to better understand their risk of developing PCa and help forecast their clinical course. In this review, we examine the current literature evaluating biomarkers in PCa. We also address current limitations and present several ideas for future studies.

• Publication year

  2015

• Venue

  Future Science OA

• Publication date

  2015-12-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4155/fso.15.72PMID 28031932PMCID 5137959
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

  2016cited by this paper
• Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

  2015cited by this paper
• Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue

  2015cited by this paper
• Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

  2015cited by this paper
• Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans

  2015cited by this paper
• A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

  2015cited by this paper
• Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

  2015cited by this paper
• Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

  2015cited by this paper
• Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer

  2015cited by this paper
• A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer

  2015cited by this paper
• The prostate health index selectively identifies clinically significant prostate cancer.

  2015cited by this paper
• Spatial genomic heterogeneity within localized, multifocal prostate cancer

  2015cited by this paper
• Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

  2015cited by this paper
• Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

  2015cited by this paper
• Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

  2015cited by this paper
• PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience

  2015cited by this paper
• Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

  2015cited by this paper
• PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

  2015cited by this paper
• Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

  2014cited by this paper
• Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer.

  2014cited by this paper
• Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.

  2014cited by this paper
• A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

  2014cited by this paper
• High‐resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer

  2014cited by this paper
• The role of metabolic imaging in radiation therapy of prostate cancer

  2014cited by this paper
• Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

  2014cited by this paper
• Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

  2014cited by this paper
• Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy

  2014cited by this paper
• J Urol

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥100.

  2014cited by this paper
• Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort

  2014cited by this paper
• A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

  2014cited by this paper
• ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.

  2014cited by this paper
• ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients

  2014cited by this paper
• TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.

  2014cited by this paper
• KLK3, PCA3, and TMPRSS2‐ERG expression in the peripheral blood mononuclear cell fraction from castration‐resistant prostate cancer patients and response to docetaxel treatment

  2014cited by this paper
• A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer.

  2014cited by this paper
• Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• Differences in ureteroscopic stone treatment and outcomes for distal, mid-, proximal, or multiple ureteral locations: the Clinical Research Office of the Endourological Society ureteroscopy global study.

  2014cited by this paper
• Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

  2014cited by this paper
• Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.

  2014cited by this paper
• PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy

  2014cited by this paper
• 346 KLK3, PCA3 and TMPRSS2-ERG expression in peripheral blood mononuclear cells from castration-resistant prostate cancer patients and response to docetaxel treatment

  2014cited by this paper
• Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.

  2014cited by this paper
• Overdetection in screening for prostate cancer

  2014cited by this paper
• Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry

  2014cited by this paper
• Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

  2014cited by this paper
• Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

  2014cited by this paper
• TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers

  2014cited by this paper
• Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

  2014cited by this paper
• Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.

  2014cited by this paper
• The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort

  2013cited by this paper
• Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

  2013cited by this paper
• The mutational landscape of prostate cancer.

  2013cited by this paper
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013cited by this paper
• Comprehensive analysis of post‐diagnostic prostate‐specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients

  2013cited by this paper
• Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness

  2013cited by this paper
• Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

  2013cited by this paper
• Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.

  2013cited by this paper
• Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy

  2013cited by this paper
• Changes in serum prostate‐specific antigen levels and the identification of prostate cancer in a large managed care population

  2013cited by this paper
• TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

  2013cited by this paper
• A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

  2013cited by this paper
• Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

  2013cited by this paper
• Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

  2013cited by this paper
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

  2013cited by this paper
• A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.

  2013cited by this paper
• Prostate cancer overdiagnosis and overtreatment

  2013cited by this paper
• Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.

  2013cited by this paper
• Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study

  2013cited by this paper
• Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer

  2013cited by this paper
• Genetic markers associated with early cancer‐specific mortality following prostatectomy

  2013cited by this paper
• The Epigenetic promise for prostate cancer diagnosis

  2012cited by this paper
• ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

  2012cited by this paper
• PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer⋆

  2012cited by this paper
• Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

  2012cited by this paper
• Publication of tumor marker research results: the necessity for complete and transparent reporting.

  2012cited by this paper
• Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

  2012cited by this paper
• Copy number alterations of c‐MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy

  2012cited by this paper
• Germline mutations in HOXB13 and prostate-cancer risk.

  2012cited by this paper
• The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

  2012cited by this paper
• Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer

  2012cited by this paper
• Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

  2012cited by this paper
• Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

  2012cited by this paper
• A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

  2012cited by this paper
• Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

  2012cited by this paper
• Circulating miRNAs are correlated with tumor progression in prostate cancer

  2011cited by this paper
• Circulating Tumor Cells as Biomarkers in Prostate Cancer

  2011cited by this paper
• NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy

  2011cited by this paper
• A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

  2011cited by this paper
• HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer

  2011cited by this paper
• Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer.

  2011cited by this paper
• Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

  2011cited by this paper
• Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

  2011cited by this paper
• TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

  2011cited by this paper
• SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

  2011cited by this paper
• ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

  2011cited by this paper
• Epigenetics in prostate cancer: biologic and clinical relevance.

  2011cited by this paper
• Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

  2011cited by this paper

• Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions

  2025influential citation
• Navigating the winding road toward precision prostate cancer care.

  2025cites this paper
• Exosomal miRNAs versus circulating tumor DNA: diagnostic accuracy for early detection of recurrence post-radical prostatectomy: A narrative review

  2025cites this paper
• Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics

  2025cites this paper
• Effect of different salt additions on the taste and flavor-related compounds in chicken soup

  2024cites this paper
• Incidence of dural metastases in castrate-resistant prostate cancer

  2024cites this paper
• Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression

  2024cites this paper
• Transforming Diagnosis and Therapeutics Using Cancer Genomics.

  2023cites this paper
• Comparison of the Fatty Acid Composition and Small Molecular Metabolites between Yanjin Blackbone Chicken and Piao Chicken Meat

  2023cites this paper
• Comparative Characterization of Volatile Compounds of Ningxiang Pig, Duroc and Their Crosses (Duroc × Ningxiang) by Using SPME-GC-MS

  2023cites this paper
• Study of Immunohistochemical Marker Psma and Ki 67 Expression and Its Relation with Grading in Prostate Carcinoma

  2022cites this paper
• A Comparison of Different Tissues Identifies the Main Precursors of Volatile Substances in Chicken Meat

  2022cites this paper
• Identification of the main aroma compounds in Chinese local chicken high-quality meat.

  2021cites this paper
• Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

  2021cites this paper
• Glycosylation: Rising Potential for Prostate Cancer Evaluation

  2021cites this paper
• Plasma Metabolomics for Discovery of Early Metabolic Markers of Prostate Cancer Based on Ultra-High-Performance Liquid Chromatography-High Resolution Mass Spectrometry

  2021cites this paper
• LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer

  2021cites this paper
• Characterisation of the main PSA glycoforms in aggressive prostate cancer

  2020cites this paper
• Quantitative SWATH-Based Proteomic Profiling for Identification of Mechanism-Driven Diagnostic Biomarkers Conferring in the Progression of Metastatic Prostate Cancer

  2020cites this paper
• Design and fabrication of a microfluidic chip to detect tumor markers

  2020cites this paper
• Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years.

  2019cites this paper
• Predictive value of pseudouridine in prostate cancer.

  2019cites this paper
• Prognostic value of tumor growth kinetic parameters in prostate cancer patients

  2019cites this paper
• Disparities in prostate cancer incidence and mortality rates: Solvable or not?

  2019cites this paper
• A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor

  2019cites this paper
• Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer

  2019cites this paper
• APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer

  2018cites this paper
• RNA‐based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP‐2 upregulation for a subsequent prostate cancer diagnosis

  2018cites this paper
• The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature

  2018cites this paper
• Genome-Based Classification and Therapy of Prostate Cancer

  2018cites this paper
• Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis

  2018cites this paper
• The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer

  2018cites this paper
• Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy

  2017cites this paper
• Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

  2017cites this paper
• Wie weit sind die molekularen Marker beim Prostatakarzinom?

  2017cites this paper
• Wie weit sind die molekularen Marker beim Prostatakarzinom?

  2017cites this paper
• Genetic and genomic technologies and diagnosis of aggressive prostate cancer

  2017cites this paper
• Functional Validation of MicroRNAs Correlated with Second Biochemical Recurrence After Post-Prostatectomy Radiation in Prostate Cancer

  2017cites this paper
• Investigating engrailed-2 (EN2) as a therapeutic target in prostate cancer

  2017cites this paper
• Genetic basis of prostate cancer: Association studies

  2017cites this paper